EDEN PRAIRIE, Minn., April 27, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders today announced that, effective April 21, 2023, the Compensation Committee of the Board of Directors approved an equity award under the NeuroOne Medical Technologies Corporation 2021 Inducement Plan (the “Inducement Plan”), as a material inducement to one individual entering into employment with the Company. The equity award was approved in accordance with Nasdaq Listing Rule 5635(c)(4), which also requires a public announcement of awards that are not made under a stockholder approved equity plan.
In connection with entering into employment with NeuroOne, the individual, who was not previously an employee or director of NeuroOne, received an option to purchase 15,000 shares of the Company’s common stock. The option award has an exercise price of $1.59 per share, the closing price of NeuroOne’s common stock on April 21, 2023, the date of the grant. The option has a ten-year term and vests as to 25% on the first anniversary of the new hire’s start date, with the remaining shares vesting in equal quarterly installments on the last day of each quarter over the next twelve (12) quarters, provided the new hire’s employment is continuing on each such date.
About NeuroOne
NeuroOne Medical Technologies Corporation is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. For more information, visit https://www.n1mtc.com.
Contact:
800-631-4030
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$0.83 |
Daily Change: | -0.08 -8.33 |
Daily Volume: | 23,815 |
Market Cap: | US$25.700M |
October 31, 2024 September 10, 2024 September 05, 2024 August 14, 2024 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB